CLINICAL TRIALS PROFILE FOR STRONTIUM CHLORIDE SR-89
✉ Email this page to a colleague
All Clinical Trials for STRONTIUM CHLORIDE SR-89
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00024167 ↗ | Chemotherapy With or Without Strontium-89 in Treating Patients With Prostate Cancer | Terminated | National Cancer Institute (NCI) | Phase 3 | 2002-04-01 | RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radioactive substances such as strontium-89 may relieve bone pain associated with prostate cancer. It is not yet known whether chemotherapy is more effective with or without strontium-89 in treating bone metastases. PURPOSE: This randomized phase III trial is studying giving chemotherapy together with strontium-89 to see how well it works compared to chemotherapy alone in treating patients with prostate cancer that has spread to the bone. |
| NCT00024167 ↗ | Chemotherapy With or Without Strontium-89 in Treating Patients With Prostate Cancer | Terminated | M.D. Anderson Cancer Center | Phase 3 | 2002-04-01 | RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radioactive substances such as strontium-89 may relieve bone pain associated with prostate cancer. It is not yet known whether chemotherapy is more effective with or without strontium-89 in treating bone metastases. PURPOSE: This randomized phase III trial is studying giving chemotherapy together with strontium-89 to see how well it works compared to chemotherapy alone in treating patients with prostate cancer that has spread to the bone. |
| NCT00080782 ↗ | Doxorubicin and Strontium-89 With or Without Celecoxib in Treating Patients With Progressive Androgen-Independent Prostate Cancer and Bone Metastases | Terminated | National Cancer Institute (NCI) | Phase 2 | 2002-02-01 | RATIONALE: Drugs used in chemotherapy, such as doxorubicin, work in different ways to stop tumor cells from dividing so they stop growing or die. Strontium-89 may relieve bone pain caused by prostate cancer. Celecoxib may stop the growth of cancer by stopping blood flow to the tumor and by blocking the enzymes necessary for tumor cell growth. Combining doxorubicin and strontium-89 with celecoxib may kill more tumor cells. PURPOSE: This randomized phase II trial is studying celecoxib together with doxorubicin and strontium-89 to see how well they work compared to doxorubicin and strontium-89 alone in treating patients with progressive androgen-independent prostate cancer and bone metastases. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for STRONTIUM CHLORIDE SR-89
Condition Name
Clinical Trial Locations for STRONTIUM CHLORIDE SR-89
Trials by Country
Clinical Trial Progress for STRONTIUM CHLORIDE SR-89
Clinical Trial Phase
Clinical Trial Sponsors for STRONTIUM CHLORIDE SR-89
Sponsor Name
